Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens

Stuart E. Siegel, Anjali Advani, Nita Seibel, Lori Muffly, Wendy Stock, Selina Luger, Bijal Shah, Daniel J. DeAngelo, David R. Freyer, Dan Douer, Rebecca H. Johnson, Brandon Hayes-Lattin, Mark Lewis, Jerry J. Jaboin, Peter F. Coccia, Archie Bleyer

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

For young adults with acute lymphoblastic leukemia, pediatric-based regimens are likely to provide the following when compared to hyper-CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality-adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper-CVAD regimens for the treatment of Philadelphia-negative B-precursor or T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.

Original languageEnglish (US)
Pages (from-to)1254-1266
Number of pages13
JournalAmerican Journal of Hematology
Volume93
Issue number10
DOIs
StatePublished - Oct 2018

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens'. Together they form a unique fingerprint.

Cite this